These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. A charitable access program for patients with lysosomal storage disorders in underserved communities worldwide. Mehta A; Ramaswami U; Muenzer J; Giugliani R; Ullrich K; Collin-Histed T; Panahloo Z; Wellhoefer H; Frader J Orphanet J Rare Dis; 2021 Jan; 16(1):8. PubMed ID: 33407729 [TBL] [Abstract][Full Text] [Related]
12. The role of antibodies in enzyme treatments and therapeutic strategies. Bigger BW; Saif M; Linthorst GE Best Pract Res Clin Endocrinol Metab; 2015 Mar; 29(2):183-94. PubMed ID: 25987172 [TBL] [Abstract][Full Text] [Related]
13. Treatment for LSDs: no longer just enzyme replacement therapy for Gaucher disease. Foreword. Cohen IJ; Baris H; Mistry PK Pediatr Endocrinol Rev; 2013 Nov; 11 Suppl 1():58. PubMed ID: 24380122 [No Abstract] [Full Text] [Related]
15. Glycomimetic-based pharmacological chaperones for lysosomal storage disorders: lessons from Gaucher, GM1-gangliosidosis and Fabry diseases. Sánchez-Fernández EM; García Fernández JM; Mellet CO Chem Commun (Camb); 2016 Apr; 52(32):5497-515. PubMed ID: 27043200 [TBL] [Abstract][Full Text] [Related]
16. Overcoming the Next Barriers to Successful Therapy. Cohen IJ; Baris H; Mistry PK; Sands MS Pediatr Endocrinol Rev; 2016 Jun; 13 Suppl 1():629. PubMed ID: 27491209 [No Abstract] [Full Text] [Related]
17. Patients' view on gene therapy development for lysosomal storage disorders: a qualitative study. Eskes ECB; Beishuizen CRL; Corazolla EM; van Middelaar T; Brands MMMG; Dekker H; van de Mheen E; Langeveld M; Hollak CEM; Sjouke B Orphanet J Rare Dis; 2022 Oct; 17(1):383. PubMed ID: 36271424 [TBL] [Abstract][Full Text] [Related]
18. Evaluation of endocrinological involvement and metabolic status in patients with Gaucher disease Type 1 and Fabry disease under enzyme replacement therapy. Ersoy M; Pişkinpaşa H J Pediatr Endocrinol Metab; 2022 Apr; 35(4):519-527. PubMed ID: 35245971 [TBL] [Abstract][Full Text] [Related]
19. Treatable lysosomal storage diseases in the advent of disease-specific therapy. Peters H; Ellaway C; Nicholls K; Reardon K; Szer J Intern Med J; 2020 Nov; 50 Suppl 4():5-27. PubMed ID: 33210402 [TBL] [Abstract][Full Text] [Related]